Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - lymfóm b-buniek - antineoplastické činidlá - polivy v kombinácii s bendamustine a rituximab je indikovaný na liečbu dospelých pacientov s relapsed/žiaruvzdorné plošných veľké b-buniek lymfóm (dlbcl), ktorí nie sú kandidátmi na hematopoetickú transplantácii kmeňových buniek. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastické činidlá - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - lymfóm, folikulárny - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastické činidlá - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - antineoplastické činidlá - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - viacnásobný myelóm - antineoplastické činidlá - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastické činidlá - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - mogamulizumab - sezary syndrome; mycosis fungoides - antineoplastické činidlá - poteligeo je indikovaný na liečbu dospelých pacientov s mycosis fungoides (mf) alebo sézary syndróm (ss), ktorí dostali aspoň jeden pred systémová terapia.

Den Europæiske Union - slovakisk - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - viacnásobný myelóm - antineoplastické činidlá - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.